FR2118123A1 - - Google Patents
Info
- Publication number
- FR2118123A1 FR2118123A1 FR7145231A FR7145231A FR2118123A1 FR 2118123 A1 FR2118123 A1 FR 2118123A1 FR 7145231 A FR7145231 A FR 7145231A FR 7145231 A FR7145231 A FR 7145231A FR 2118123 A1 FR2118123 A1 FR 2118123A1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB6007070 | 1970-12-17 | ||
| GB6006470A GB1380246A (en) | 1970-12-17 | 1970-12-17 | 3alpha-hydroxy-androstanes and esters thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2118123A1 true FR2118123A1 (enExample) | 1972-07-28 |
| FR2118123B1 FR2118123B1 (enExample) | 1975-11-28 |
Family
ID=26267810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7145231A Expired FR2118123B1 (enExample) | 1970-12-17 | 1971-12-16 |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU473307B2 (enExample) |
| BE (1) | BE776791A (enExample) |
| DE (1) | DE2162595A1 (enExample) |
| FR (1) | FR2118123B1 (enExample) |
| GB (1) | GB1380246A (enExample) |
| IL (1) | IL38378A (enExample) |
| NL (1) | NL7117256A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2189034A2 (enExample) * | 1972-06-15 | 1974-01-25 | Glaxo Lab Ltd |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| HUE051403T2 (hu) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| LT3021852T (lt) | 2013-07-19 | 2021-04-12 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas |
| EP3035940B1 (en) | 2013-08-23 | 2018-10-17 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN112961206A (zh) | 2014-10-16 | 2021-06-15 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| HUE049014T2 (hu) | 2014-11-27 | 2020-09-28 | Sage Therapeutics Inc | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| NZ790225A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| WO2019126741A1 (en) * | 2017-12-22 | 2019-06-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| JP2021506904A (ja) * | 2017-12-22 | 2021-02-22 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置のための組成物および方法 |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
-
1970
- 1970-12-17 GB GB6006470A patent/GB1380246A/en not_active Expired
-
1971
- 1971-12-16 NL NL7117256A patent/NL7117256A/xx unknown
- 1971-12-16 AU AU36958/71A patent/AU473307B2/en not_active Expired
- 1971-12-16 FR FR7145231A patent/FR2118123B1/fr not_active Expired
- 1971-12-16 BE BE776791A patent/BE776791A/xx unknown
- 1971-12-16 IL IL7138378A patent/IL38378A/xx unknown
- 1971-12-16 DE DE19712162595 patent/DE2162595A1/de not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| NEANT * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2189034A2 (enExample) * | 1972-06-15 | 1974-01-25 | Glaxo Lab Ltd |
Also Published As
| Publication number | Publication date |
|---|---|
| AU473307B2 (en) | 1976-06-17 |
| FR2118123B1 (enExample) | 1975-11-28 |
| AU3695871A (en) | 1973-06-21 |
| DE2162595A1 (de) | 1972-07-06 |
| BE776791A (fr) | 1972-06-16 |
| GB1380246A (en) | 1975-01-08 |
| IL38378A (en) | 1979-01-31 |
| NL7117256A (enExample) | 1972-06-20 |
| IL38378A0 (en) | 1972-02-29 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |